Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels are associated with acute ischemic stroke severity

Kang, Yang Ho; Park, Min-Gyu; Noh, Kyung-Ha; Park, Hae Rim; Lee, Hye Won; Son, Seok Man; Park, Kyung-Pil

doi:10.1016/j.atherosclerosis.2015.03.028

Cited by 22 publications

(23 citation statements)

References 26 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a study performed in plasma samples of patients with recent lacunar infarcts (silent brain infarcts) revealed no significant difference in TRAIL levels with respect to healthy controls [ 121 ]. Nonetheless, in a recently published study performed in a cohort of patients with acute ischemic stroke, significant negative correlations between serum TRAIL levels and both clinical score and stroke volume have been reported, with no difference between the various stroke subtypes analysed, in line with findings reported in other cardiovascular diseases [ 122 ].…”

Section: Introductionsupporting

confidence: 65%

Clinical perspectives of TRAIL: insights into central nervous system disorders

Tisato

Gonelli

Voltan

et al. 2016

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

The TNF-related apoptosis inducing ligand TRAIL is a member of the TNF superfamily that has been firstly studied and evaluated for its anti-cancer activity, and the insights into its biology have already led to the identification of several TRAIL-based anticancer strategies with strong clinical therapeutic potentials. Nonetheless, the TRAIL system is far more complex and it can lead to a wider range of biological effects other than the ability of inducing apoptosis in cancer cells. By virtue of the different receptors and the different signalling pathways involved, TRAIL plays indeed a role in the regulation of different processes of the innate and adaptive immune system and this feature makes it an intriguing molecule under consideration in the development/progression/treatment of several immunological disorders. In this context, central nervous system represents a peculiar anatomic site where, despite its “status” of immune-privileged site, both innate and adaptive inflammatory responses occur and are involved in several pathological conditions. A number of studies have evaluated the role of TRAIL and of TRAIL-related pathways as pro-inflammatory or protective stimuli, depending on the specific pathological condition, confirming a twofold nature of this molecule. In this light, the aim of this review is to summarize the main preclinical evidences of the potential/involvement of TRAIL molecule and TRAIL pathways for the treatment of central nervous system disorders and the key suggestions coming from their assessment in preclinical models as proof of concept for future clinical studies.

show abstract

Section: Introductionsupporting

confidence: 65%

Clinical perspectives of TRAIL: insights into central nervous system disorders

Tisato

Gonelli

Voltan

et al. 2016

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

show abstract

“…Mild stroke was defined as an NIHSS score < 8, and moderate-to-severe stroke was defined as an NIHSS score ≥ 8, consistent with the existing literature 36 , 37 . The infarct volume was evaluated in 151 patients using the initial diffusion-weighted imaging lesion volume and was calculated as the sum of the infarcted area of every slice multiplied by the slice thickness, based on several previous studies 38 , 39 . Structured telephone follow-ups were conducted by one doctor who was blinded to the patients’ clinical information.…”

Section: Methodsmentioning

confidence: 99%

Longitudinal evaluation of serum periostin levels in patients after large-artery atherosclerotic stroke: A prospective observational study

Bao

Shen

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Increasing evidence supports the involvement of periostin in the pathophysiological processes of stroke and atherosclerosis. The aim of this study was to assess circulating periostin levels at different times after large-artery atherosclerotic (LAA) stroke and their association with stroke. Serum periostin levels were measured using enzyme-linked immunosorbent assay on day 1 in 162 patients with LAA stroke and in 108 age- and sex-matched controls, on day 6 after stroke in 134 patients, and during the 4th week after stroke in 46 of the 162 patients. Stroke severity was determined using the National Institutes of Health Stroke Scale (NIHSS), and the stroke volume was measured. Outcome at 3 months was measured using the modified Rankin Scale (mRS). Our results indicated that periostin levels increased significantly on day 6 after stroke, and this increasing trend persisted for at least 4 weeks after the event. In addition, the increase in periostin levels was positively correlated with the NIHSS scores and stroke volume, but not with the mRS scores after adjusting for the NIHSS scores. In conclusion, these findings suggest that the increase in serum periostin levels observed after stroke may be associated with the stroke severity in patients with LAA stroke.

show abstract

“…Stroke aetiology was defined according to TOAST (Trial of Org 10172 in Acute Stroke Treatment) 38 criteria by experienced clinicians at the time of patient admission. The infarct volume was evaluated in 120 patients using the initial DWI lesion volume and calculated as the sum of the infarction area of every slice multiplied by the slice thickness 39 , 40 .…”

Section: Methodsmentioning

confidence: 99%

High Serum Levels of Malondialdehyde and 8-OHdG are both Associated with Early Cognitive Impairment in Patients with Acute Ischaemic Stroke

Liu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Post-stroke cognitive impairment (PSCI) is an increasingly prevalent sequel after stroke that may associate with poor functional outcome and increased risk of recurrent stroke. We aimed to explore the relationship between oxidative stress biomarkers and the presence of PSCI. 193 first-ever acute ischaemic stroke patients were consecutively enrolled in the current study. The oxidative stress biomarkers malondialdehyde (MDA) and 8-hydroxydeoxyquanosine (8-OHdG) were measured within 24 h after admission. Cognition function was evaluated by the Mini-Mental State Examination (MMSE) at 1 month after stroke. Serum levels of 8-OHdG and MDA were both significantly higher in the PSCI (p < 0.001) compared with the non-PSCI group. Both the serum levels of both 8-OHdG and MDA were negatively correlated with the MMSE score. Receiver operating characteristic curve analysis was used to evaluate 8-OHdG and MDA as markers of a high risk of PSCI and produced area under curve values of 0.700 and 0.793. Adjusted logistic regression showed that serum 8-OHdG and MDA levels remained as independent markers of PSCI. High serum levels of malondialdehyde and 8-OHdG are associated with the presence of PSCI at 1 month after stroke.Cognitive impairment is an increasingly prevalent sequel after stroke 1 , even in those with successful clinical recovery 2 . The diagnosis of post-stroke cognitive impairment (PSCI) deserves wide attention because the presence of cognitive impairment has been associated with poor functional outcome 2 and a higher risk of future stroke 3 . However, traditional known risk factors of PSCI, including older age, sex differences and a previous history of stroke 4 , are not readily amenable to treatment. Therefore, it is essential to identify pathophysiological mechanisms that may result in PSCI, especially in the early stage of stroke; however, research into the biochemical changes in PSCI is still not systematic and is lacking in both quality and quantity.Increasing evidence has demonstrated the vital role of oxidative stress pathways in the regulation of cognitive impairment related processes, including vascular inflammation 5 , neurodegeneration 6 , and blood-brain barrier (BBB) dysfunction 7 , all of which indicate the potential relationship between oxidative stress pathways and cognitive impairment.The oxidative stress pathway can produce oxidative damage of lipids and nucleic acids. 8-hydroxydeoxyquanosine (8-OHdG) and malondialdehyde (MDA) are common end-products of deoxyribonucleic acid (DNA) oxidation and lipid peroxidation, respectively, and can be detected in body fluid or brain in humans 8 . The systemic oxidative stress response to acute ischaemic stroke involves increases in 8-OHdG and MDA, which have also been associated with poor functional recovery 9 and mortality 10 . While higher peripheral blood levels of 8-OHdG 11 and MDA 12 have been associated with dementia, and some researchers have found that oxidative stress is related to cognition, without dementia or stroke 13 , the association between 8-OHdG...

show abstract

Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels are associated with acute ischemic stroke severity

Cited by 22 publications

References 26 publications

Clinical perspectives of TRAIL: insights into central nervous system disorders

Clinical perspectives of TRAIL: insights into central nervous system disorders

Longitudinal evaluation of serum periostin levels in patients after large-artery atherosclerotic stroke: A prospective observational study

High Serum Levels of Malondialdehyde and 8-OHdG are both Associated with Early Cognitive Impairment in Patients with Acute Ischaemic Stroke

Contact Info

Product

Resources

About